Investment: Should you invest in... pharmaceutical companies?

the pharmaceuticals sector has been a source of strong growth, despite the potentially high-risk nature of a business heavily dependent on research and development of new products, and patent protection. The more mature business of chemicals manufacture has also been largely out of favour.

Glenn Meyer of Pavilion Asset Management says: "The two sectors seem to act in opposition. Pharmaceuticals are generally growth stocks and chemical companies tend to be highly cyclical. Pharmaceuticals have a much clearer and longer flow of earnings, and the chemical sector moves in line with the world economy and is much more volatile."

Jeremy Batstone of NatWest Stockbrokers has a different focus."Pharmaceuticals have been very volatile and the sector has tended to lag the market," he says. "People are looking more for value as the economy has improved, away from more defensive growth areas like pharmaceuticals."

Mark Mathias, head of investment funds at Rea Brothers Investment Management, agrees the sector's long-term growth potential is undisputed. Mathias, whose firm runs two specialist pharmaceutical funds, says: "There is the trend to ageing populations in the OECD countries, with the highest proportion of lifetime healthcare expenditure coming in the last two years of life, underpinned by the significant increase in healthcare research expenditure. At the same time, the OECD governments are trying to rein in the cost of government-subsidised healthcare and the way you do that is to spend more on drugs to keep people out of hospital."

North America's political debate about state-funded medical programmes has added to the uncertainty, says Nigel Thomas, manager of ABN Amro's UK Growth Fund. "Proposed legislation in Medicare reform will limit spending on outpatient drug costs for elderly people who account for over 30 per cent of US outpatient drug spending and this will affect pharmaceutical companies - the FT suggests it would impact earnings by between 10 and 15 per cent."

Thomas says the plans will probably not come to fruition but the debate is affecting share prices. "It is a political hot potato but given the Republican position in Congress, we are not so sure it will be enacted."

Size is also going to be a key element in future corporate earnings. "When it comes down to it, healthcare is not an optional expenditure and the amounts spent on it are going to rise," adds Mathias.

"There is very good long-term earnings visibility in the pharmaceutical sector andmergers of large companies. You can sell the same drugs into different markets, and IT helps keep control in multinational companies."

Batstone says: "There is still a lot of scope for mergers and acquisitions in the pharmaceutical sector. Critical mass is the key force driving consolidation because of the large spend on R&D. The quicker you can develop a new drug from scratch, the longer you will have the benefit of its patent protection, but without the scale you haven't got the size or funds for research."

Every major player is in the frame. "SmithKline Beecham is mentioned on a fairly regular basis but Glaxo Wellcome is also rumoured to be looking at an overseas tie-up," he adds.

Glenn Meyer says: "The UK chemical sector has underperformed the market, but overseas firms seem to value UK chemical companies more highly than the market does."

Stock selection is the key. "Concentrate on chemical sector stocks which focus on profitable areas, such as BTP, which constantly refreshes its portfolio," he says. "Avoid larger companies, which tend to underperform the market."

There is scope for the active share trader. Meyer adds: "ICI has been a relatively poor performer for a long time, but with short periods of outperformance, so timing is everything. Look at manufacturers of industrial chemicals. The problem here is that you very quickly reach overcapacity and have a fairly low return on capital."

By contrast, the bulk of investor interest in the drugs sector is focused on the largest stocks. Nigel Thomas says: "There aren't that many pure pharmaceutical companies below pounds 1bn in size. Shire Pharmaceuticals and Medeva, with Galen in Ireland, are the only mid-sized ones and once below a certain size they are largely bio-techs, of which we like Celltech and Phytopharm."

Jeremy Batstone adds: "There are a lot of stocks in the sector relatively cheap, with the possible exception of AstraZeneca. Glaxo Wellcome still looks good value at around pounds 19. We would suggest it could get up to maybe pounds 21.50 or pounds 22 in the short to medium term."

Another key player in the sector is SmithKline Beecham, where investors were holding off until the US Food & Drug Administration (FDA) ruled on Avandia, its new diabetes treatment, last week. Batstone adds: "The ruling was positive and SmithKline could be looking at sales of $1.5bn to $2bn."

Susan Sarandon described David Bowie as
peopleSusan Sarandon reveals more on her David Bowie romance
Arsenal supporters gather for a recent ‘fan party’ in New Jersey
sportDidier Drogba returns to Chelsea on one-year deal
Arts and Entertainment
The Secret Cinema performance of Back to the Future has been cancelled again
Life and Style
Balmain's autumn/winter 2014 campaign, shot by Mario Sorrenti and featuring Binx Walton, Cara Delevingne, Jourdan Dunn, Ysaunny Brito, Issa Lish and Kayla Scott
fashionHow Olivier Rousteing is revitalising the house of Balmain
Arts and Entertainment
Christian Grey cradles Ana in the Fifty Shades of Grey film
filmFifty Shades of Grey trailer provokes moral outrage in US
BBC broadcaster and presenter Evan Davis, who will be taking over from Jeremy Paxman on Newsnight
peopleForget Paxman - what will Evan Davis be like on Newsnight?
Life and Style
fashionCustomer complained about the visibly protruding ribs
The new dawn heralded by George Osborne has yet to rise
voicesJames Moore: As the Tories rub their hands together, the average voter will be asking why they're not getting a piece of the action
Dejan Lovren celebrates scoring for Southampton although the goal was later credited to Adam Lallana
newsComedy club forced to apologise as maggots eating a dead pigeon fall out of air-conditioning
Arts and Entertainment
Jo Brand says she's mellowed a lot
tvJo Brand says shows encourage people to laugh at the vulnerable
Life and Style
People may feel that they're procrastinating by watching TV in the evening
ebookA unique anthology of reporting and analysis of a crucial period of history
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Senior Risk Manager - Banking - London - £650

£600 - £650 per day: Orgtel: Conduct Risk Liaison Manager - Banking - London -...

The benefits of being in Recruitment at SThree...

£18000 - £23000 per annum + Comission: SThree: SThree, International Recruitme...

Test Analyst - UAT - Credit Risk

£280 - £300 per day + competitive: Orgtel: Test Analyst, Edinburgh, Credit Ris...

Trainee Recruitment Consultants - Banking & Finance

£20000 - £25000 per annum + OTE £40,000: SThree: SThree Group have been well e...

Day In a Page

Evan Davis: The BBC’s wolf in sheep’s clothing to take over at Newsnight

The BBC’s wolf in sheep’s clothing

What will Evan Davis be like on Newsnight?
Finding the names for America’s shame: What happens to the immigrants crossing the US-Mexico border without documents who never make it past the Arizona desert?

Finding the names for America’s shame

The immigrants crossing the US-Mexico border without documents who never make it past the Arizona desert
Inside a church for Born Again Christians: Speaking to God in a Manchester multiplex

Inside a church for Born Again Christians

As Britain's Anglican church struggles to establish its modern identity, one branch of Christianity is booming
Rihanna, Kim Kardashian and me: How Olivier Rousteing is revitalising the house of Balmain

Olivier Rousteing is revitalising the house of Balmain

Parisian couturier Pierre Balmain made his name dressing the mid-century jet set. Today, Olivier Rousteing – heir to the house Pierre built – is celebrating their 21st-century equivalents. The result? Nothing short of Balmania
Cancer, cardiac arrest, HIV and homelessness - and he's only 39

Incredible survival story of David Tovey

Tovey went from cooking for the Queen to rifling through bins for his supper. His is a startling story of endurance against the odds – and of a social safety net failing at every turn
Backhanders, bribery and abuses of power have soared in China as economy surges

Bribery and abuses of power soar in China

The bribery is fuelled by the surge in China's economy but the rules of corruption are subtle and unspoken, finds Evan Osnos, as he learns the dark arts from a master
Commonwealth Games 2014: Highland terriers stole the show at the opening ceremony

Highland terriers steal the show at opening ceremony

Gillian Orr explores why a dog loved by film stars and presidents is finally having its day
German art world rocked as artists use renowned fat sculpture to distil schnapps

Brewing the fat from artwork angers widow of sculptor

Part of Joseph Beuys' 1982 sculpture 'Fettecke' used to distil schnapps
BBC's The Secret History of Our Streets reveals a fascinating window into Britain's past

BBC takes viewers back down memory lane

The Secret History of Our Streets, which returns with three films looking at Scottish streets, is the inverse of Benefits Street - delivering warmth instead of cynicism
Joe, film review: Nicolas Cage delivers an astonishing performance in low budget drama

Nicolas Cage shines in low-budget drama Joe

Cage plays an ex-con in David Gordon Green's independent drama, which has been adapted from a novel by Larry Brown
How to make your own gourmet ice lollies, granitas, slushy cocktails and frozen yoghurt

Make your own ice lollies and frozen yoghurt

Think outside the cool box for this summer's tempting frozen treats
Ford Fiesta is UK's most popular car of all-time, with sales topping 4.1 million since 1976

Fiesta is UK's most popular car of all-time

Sales have topped 4.1 million since 1976. To celebrate this milestone, four Independent writers recall their Fiestas with pride
10 best reed diffusers

Heaven scent: 10 best reed diffusers

Keep your rooms smelling summery and fresh with one of these subtle but distinctive home fragrances that’ll last you months
Commonwealth Games 2014: Female boxers set to compete for first time

Female boxers set to compete at Commonwealth Games for first time

There’s no favourites and with no headguards anything could happen
Five things we’ve learned so far about Manchester United under Louis van Gaal

Five things we’ve learned so far about United under Van Gaal

It’s impossible to avoid the impression that the Dutch manager is playing to the gallery a little